The updated US guidelines for high blood pressure (HBP) emphasize that HBP is the most common and modifiable risk factor for cardiovascular diseases—including coronary artery disease, heart failure, atrial fibrillation, stroke, dementia, chronic kidney disease, and all-cause mortality—with a treatment goal of <130/80 mm Hg for most adults, while allowing […]
The number of individuals with high blood pressure (BP) is increasing worldwide. The trajectory of BP control appears to be worsening in North America, some European countries, and elsewhere around the world. The risk for cardiovascular diseases (CVD) attributable to BP is on a continuous log-linear exposure variable scale, not […]
The US guideline for the management of hypertrophic cardiomyopathy (HCM) have been updated. The top 10 take-home messages are: Shared decision-making is essential to provide the best clinical care. Referral to multidisciplinary HCM centers with appropriate expertise can be important to optimizing care for patients with HCM. Careful ascertainment of […]
The US 2023 atrial fibrillation (AF) guideline emphasizes a rhythm control strategy and highlight the need for lifestyle and risk factor modification in addition to medical treatment. Key points including: The new proposed classification of AF by 4 stages, recognizes AF as a disease continuum that requires a variety of […]